Key Points
- Director Kevin Rakin bought 50,000 shares on Dec. 17 at an average price of $0.52 per share for $26,000, increasing his stake to 322,419 shares — an 18.35% ownership rise.
- Market and analyst context: ELUT opened at $0.59 (50-day avg $0.76, 200-day avg $1.43) with a $25.04M market cap, roughly 74% institutional ownership, and a consensus "Hold" rating with a $7 price target.
Elutia Inc. (NASDAQ:ELUT - Get Free Report) Director Kevin Rakin acquired 50,000 shares of Elutia stock in a transaction dated Wednesday, December 17th. The stock was purchased at an average price of $0.52 per share, with a total value of $26,000.00. Following the completion of the purchase, the director owned 322,419 shares of the company's stock, valued at approximately $167,657.88. The trade was a 18.35% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Elutia Stock Up 8.0%
Elutia stock opened at $0.59 on Friday. The stock has a 50-day moving average price of $0.76 and a 200 day moving average price of $1.43. The company has a market capitalization of $25.04 million, a price-to-earnings ratio of -0.64 and a beta of 0.63. Elutia Inc. has a 52 week low of $0.50 and a 52 week high of $4.84.
Elutia (NASDAQ:ELUT - Get Free Report) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.16) by $0.15. The business had revenue of $3.32 million for the quarter, compared to analysts' expectations of $6.65 million. Research analysts anticipate that Elutia Inc. will post -1.74 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in ELUT. Virtu Financial LLC acquired a new position in shares of Elutia in the third quarter worth about $26,000. OMERS ADMINISTRATION Corp purchased a new position in shares of Elutia in the 1st quarter valued at about $28,000. XTX Topco Ltd acquired a new position in Elutia in the 2nd quarter worth about $28,000. Jane Street Group LLC acquired a new position in Elutia in the 1st quarter worth about $48,000. Finally, Citadel Advisors LLC purchased a new position in Elutia during the third quarter worth approximately $50,000. Hedge funds and other institutional investors own 74.03% of the company's stock.
Wall Street Analysts Forecast Growth
ELUT has been the topic of several recent research reports. Wall Street Zen raised shares of Elutia to a "sell" rating in a report on Saturday, November 8th. Weiss Ratings reissued a "sell (e+)" rating on shares of Elutia in a report on Wednesday, October 8th. Finally, Lake Street Capital lowered their target price on Elutia from $8.00 to $6.00 and set a "buy" rating on the stock in a research note on Wednesday, September 10th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Elutia currently has a consensus rating of "Hold" and a consensus price target of $7.00.
Get Our Latest Report on Elutia
Elutia Company Profile
(
Get Free Report)
Elutia, Inc is a biopharmaceutical company focused on the development of novel nitric oxide therapies based on its proprietary polymeric nitric oxide platform. This technology is designed to enable sustained, controlled release of nitric oxide to targeted tissues, potentially overcoming the delivery challenges associated with gaseous nitric oxide and small‐molecule donors.
The company's lead program is in preclinical development for pulmonary arterial hypertension, with additional research efforts aimed at other cardiovascular and respiratory conditions.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
